Professional Documents
Culture Documents
18-20 Nifty mostly trades in this range. Good time to gradually build-up
your portfolio.
20-22 This is also the average range. Stock selection skill is important to
maximize return.
22-24 Either market will fall by more than 10% or earning will expand.
Few selective stocks will generate positive return. (Mar 2015)
24+ Better not to invest, wait. (Sep 2016)
25+ 30%+ crash must, Investment in this period most likely generate
negative return. So book profit/exit from as many stocks as you
can. (Oct 2007 – Jan 2008, Sep-Oct 2010)
Additional Checks
• Interest rate trends. Economic slowdown
occurs during upward cycle.
• Inflation trend. Lowering inflation is good
because it will prompt lower interest rates and
higher spending.
• Higher spending leads to the expansion of
GDP.
Real Problems
Divorce? Death?
Any examples?
Why traditional valuation method won’t
work?
• Traditional valuation method includes DCF,
intrinsic value calculation etc won’t work.
• If the intrinsic value is known to all, then why
someone would like to purchase at higher rate
and if this is the case then how someone can
make profit?
• Never ever look for secret formula to figure
out valuation.
Stock specific valuation
• Traditional valuation method (including DCF, intrinsic
value calculation) won’t work.
• You have to assign fair P.E multiple.
• Fair P.E depends on market cap, type of sector and
financial strength.
• Whenever Nifty PE stays above 20, it is almost
impossible to find out all-perfect stock. You have to
compromise, assign some risk premium. (Example of
Vikas Ecotech, Srikalahasti etc)
Valuation
• Consider Pharma sector, Large cap historic P.E
range 20-30, smallcaps would be highly valued
at PE of 30. So for smallcaps, fair P.E would be
10-15. For midcaps 12-20. (Example Caplin –
2600 cr, Coral lab 200 cr)
• Transformation from smallcaps to midcap or
largecap re-rates P.E
• Also consider, the type of sector and financial
strength.
Caplin Point Lab
During May 2015 and October 2016, P.E crossed 50. During Oct, 16 annualised EPS was around 8.5.
Best case, EPS doubled within June 2018 end, i.e. 16, with PE multiple of 30, price comes 480. So,
buying position can be initiated below 300.
Finding the valuation
• Coral Lab, microcap Pharma stock having market cap
of around 200 crore. 15%+ROE, D/E near zero,
consistent growth. The only problem is, unlike Caplin
there are no management interview, future guidance
on AR and all.
• So, figuring out some growth rate from the past.
Assuming 15% EPS growth, FY17 E EPS comes around
40. Applying fair PE of 15, price comes around 600.
Applying PE of 20, it would become 800!
How to lead happy and prosperous life?